title: Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis.
authors.affiliation: Department of Medicine, University of Colorado Denver, Aurora, Colorado 80045, USA Department of Medicine, Radboud University Medical Centre, HB 6500 Nijmegen, Netherlands.
authors.forename: Charles A
authors.initials: CA
authors.lastname: Dinarello
authors.affiliation: Department of Medicine, Radboud University Medical Centre, HB 6500 Nijmegen, Netherlands.
authors.forename: Leo A B
authors.initials: LA
authors.lastname: Joosten
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015210:Arthritis, Gouty / Q000188:drug therapy* / Q000276:immunology; D061945:Caspase Inhibitors / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012219:Rheumatology / Q000639:trends; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D061945:Caspase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000515:alpha 1-Antitrypsin; C541220:canakinumab; C571216:brodalumab; C555450:secukinumab